US20070197489A1 - Composition of matter - Google Patents
Composition of matter Download PDFInfo
- Publication number
- US20070197489A1 US20070197489A1 US11/690,537 US69053707A US2007197489A1 US 20070197489 A1 US20070197489 A1 US 20070197489A1 US 69053707 A US69053707 A US 69053707A US 2007197489 A1 US2007197489 A1 US 2007197489A1
- Authority
- US
- United States
- Prior art keywords
- powder composition
- glucocorticosteroid
- heat sterilization
- budesonide
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 97
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 60
- 230000001954 sterilising effect Effects 0.000 claims abstract description 47
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 43
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 64
- 229960004436 budesonide Drugs 0.000 claims description 60
- 238000010438 heat treatment Methods 0.000 claims description 38
- 239000000843 powder Substances 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 22
- 229950004432 rofleponide Drugs 0.000 claims description 18
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000012298 atmosphere Substances 0.000 claims description 5
- 239000011261 inert gas Substances 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 9
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 7
- 230000008569 process Effects 0.000 abstract description 32
- 238000009472 formulation Methods 0.000 abstract description 24
- 230000004968 inflammatory condition Effects 0.000 abstract description 5
- 230000000172 allergic effect Effects 0.000 abstract description 4
- 208000010668 atopic eczema Diseases 0.000 abstract description 4
- 210000004072 lung Anatomy 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 15
- -1 as propionate) Chemical compound 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000002562 thickening agent Substances 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 229940068917 polyethylene glycols Drugs 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 5
- 235000013539 calcium stearate Nutrition 0.000 description 5
- 239000008116 calcium stearate Substances 0.000 description 5
- 229960005205 prednisolone Drugs 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000011146 sterile filtration Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229950000210 beclometasone dipropionate Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 201000009151 chronic rhinitis Diseases 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940072266 pulmicort Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 241000193470 Clostridium sporogenes Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000128833 Mimulus luteus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- PHEOVVDXTQVHAZ-XDANTLIUSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O PHEOVVDXTQVHAZ-XDANTLIUSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003840 cortivazol Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229950001669 tipredane Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Definitions
- This invention relates to a process for sterilization of a powdered form of a glucocorticosteroid, sterile glucocorticosteroids, sterile formulations containing glucocorticosteroids and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or lungs.
- glucocorticosteroids discloses the cold sterilization of micronized glucocorticosteroids using mixtures of ethylene oxide and carbon dioxide, since, according to PT-A-69652, steroids in powder form are not stable at temperatures above 60° C.
- Specific examples of glucorticorsteroids are prednacindone, dexamethasone and prednisolone, and salts, esters and fluoro derivatives thereof, including dexamethasone acetate, dexamethasone phosphate, prednisolone pivalate and 9-alphafluoro prednisolone.
- ethylene oxide is toxic and when it is used to sterilize glucocorticosteroids it has been found that the residual amounts of the ethylene oxide contravene pharmaceutical guidelines which require very low levels of residual ethylene oxide. Accordingly this method has been found to be unsuitable for producing therapeutically acceptable glucocorticosteroids and formulations thereof.
- U.S. Pat. No. 3,962,430 discloses a method for the production of sterile isotonic solutions of medicinal agents, which comprises adding the agent to a saturated solution of sodium chloride in water at 100° C. and then heating the mixture at 100-130° C.
- This method is not suitable for suspensions of fine particles of glucocorticosteroids which are intended for inhalation because the water, and the heating and cooling involved, produce unfavorable changes in the size of the particles. Indeed it can lead to the formation of bridges between the fine particles producing large, hard aggregates which will not deaggregate into the desired fine particles upon administration.
- a putative alternative is dry heat sterilization.
- European Pharmacopoeia (1996, pp. 283-4) a normal heat sterilization process runs at 180° C. for 30 min or at a minimum of 160° C. for at least 2 hours.
- Pharmacopoeia Nordica (1964, pp. 16) such a sterilization can be carried out at 140° C. for 3 hours.
- glucocorticosteroids suffer significant degradation and are subject to changes in their surface structure.
- WO-A-96/09814 to Andaris Ltd. relates to spray-dried particles of a water-soluble material with a mass median particle size of 1 to 10 ⁇ m.
- the aim of the invention is to produce uniform and reproducible particles for use in dry powder inhalers.
- the water-soluble material is preferably a human protein or a fragment thereof, in natural or recombinant form, e.g. human serum albumin (HSA), alpha-1 antitrypsin or alcohol dehydrogenase.
- HSA human serum albumin
- alpha-1 antitrypsin or alcohol dehydrogenase also combinations of an active material with a carrier were produced e.g. budesonide and lactose. It is stated generally that the microparticles produced can be sterile without teaching now this could or would be achieved nor showing any proof thereof.
- WO-A-96/32905 to Astra AB relates to a process for the preparation of respirable particles by dissolving an inhalation compound in a solvent, introducing the resulting solution containing the inhalation compound in droplet form or as a jet stream into an anti-solvent which is miscible with the solvent and which is under agitation.
- Budesonide with a mass median diameter (MMD) of less than 10 ⁇ m is produced with the process.
- MMD mass median diameter
- WO-A-92/11280 to Instytut Farmaceutyczny relates to a method of obtaining (22R) diasteroisomer of budesonide by a condensation reaction followed by crystallizing the crude product of condensaton from ethanol.
- the obtained 21-acetate of budesonide (22R) is hydrolyzed and the product thus obtained is crystallized from ethyl acetate.
- the content of (22S) diasteroisomer of budesonide is 1% or less.
- aqueous suspensions of finely divided glucocorticosteroids are known, e.g. the budesonide-containing product known as Pulmicort® nebulising suspension.
- Pulmicort® is a trademark of Astra AB of Sweden.
- Similar formulations of fluticasone propionate are known from WO-A-95/31964.
- a process for the sterilization of a glucocorticosteroid which process comprises heat treating the glucocorticosteroid in the form of a powder at a temperature of from 100 to 130° C.
- the process is preferably carried out at a temperature of from 110 to 120° C., more preferably at about 110° C., preferably for up to about 24 hours, more preferable up to 10 hours, e.g. from 1 to 10 hours.
- the process is conveniently carried out under atmospheric conditions, i.e. in air, but may also be carried out under an inert gas atmosphere, e.g. an atmosphere of argon or nitrogen.
- the unexpectedly low temperature at which the glucocorticosteroids can be sterilized indicates that the glucocorticosteroid may provide some synergistic effect, when taken together with the heat treatment, in destroying the spores.
- the glucocorticosteroid used in the invention is preferably an anti-inflammatory glucocorticosteroid, e.g. for use in nasal and oral inhalation.
- glucocorticosteroids which may be used in the present invention include betamethasone, fluticasone (e.g. as propionate), budesonide, tipredane, dexamethasone, beclomethasone (e.g. as dipropionate), prednisolone, fluocinolone, triamcinolone (e.g. as acetonide), momethasone (e.g. as furoate), rofleponide (e.g.
- momethasone furoate beclomethasone dipropionate or fluticasone propionate or glucocorticosteroids with an asymmetric acetal structure, i.e. comprising 16 ⁇ ,17 ⁇ -butylidenedioxy, such as budesonide, rofleponide or rofleponide palmitate.
- asymmetric acetal structure i.e. comprising 16 ⁇ ,17 ⁇ -butylidenedioxy
- budesonide, rofleponide or rofleponide palmitate Preferably, use is made of budesonide, rofleponide or rofleponide palmitate and most preferably of budesonide.
- the glucocorticosteroid is preferably used in the form of a finely divided, e.g. micronized, powder, particularly in the form of finely divided particles having a mass median diameter of less than 10 ⁇ m, more preferably less than 5 ⁇ m.
- the glucocorticosteroid may alternatively be in an ultra fine form, e.g. having a mass median diameter of less than 1.0 ⁇ m.
- the finely divided particles may be produced by conventional techniques known per se. e.g. by micronization or by direct precipitation. Information about micronization can be found e.g. in “The Theory and Practice of Industrial Pharmacy”, Lachman, Liebermann and Klang, 2 nd Ed., 1976, Lea & Febiger, Philadelphia, USA.
- the temperature, time, batch size and type of sterilizer used will be interdependent. Thus generally the higher the temperature used in the process according to the invention, the less time is required to sterilize the glucocorticosteroid.
- the process is preferably carried out for no more than 8 hours, e.g. from 1 to 8 hours, when the temperature is greater than about 110° C., more preferably no more than 4 hours. At a temperature of about 120° C. the process is preferably carried out for no more than 4 hours, e.g. from 1 to 4 hours, more preferably no more than 2 hours, e.g. from 1 to 2 hours.
- glucocorticosteroid At temperatures of from about 110° C. up to 130° C., a batch of 50 g of glucocorticosteroid may suitably be heat treated from 1 to 4 hours. If desired sub-batches, e.g. of 4 ⁇ 50 g, may be used.
- the present process may be carried out such that it results in a more than log 4 reduction in the amount of heat resistant spores.
- the process of the present invention is suitably carried out such that it results in a log 6 reduction in the amount of heat resistant spores.
- the present process is preferably carried out such that it results in a more than log 6 reduction, and more preferably such that it results in a more than log 7 reduction in the amount of heat resistant spores.
- the D value also known as the D T value, is the time (in minutes) required to reduce (“kill”) a standardized population of spores by 90% or 1 log cycle, i.e. to a survival fraction of 1/10, at a specific temperature T (in °C.).
- the present process may be carried out such that the D value is less than about 240 min at the preselected temperature T, wherein T is in the range of from 100 to 130° C.
- the process of the present invention is suitably carried out such that the D value is less than 150 min at the preselected temperature T.
- the process of the present invention is carried out such that the D value is less than 90 min at the preselected temperature T, and more preferably such that the D value is less than 30 min at the preselected temperature T.
- T is suitably 100, 110, 120 or 130° C.
- the sterilization process is desirably carried out in such a manner that all parts of the bulk of the glucocorticosteroid reaches, and is maintained within, the desired temperature for the desired time.
- the present process may be carried out batch wise or continuously, preferably batch wise.
- the glucocorticosteroid starting material for the process which material may be in finely divided form, is suitably substantially dry, i.e. containing less than about 1% (w/w) of water.
- the starting material for the process contains less than 0.5% (w/w) of water, and more preferably less than 0.3% (w/w) of water.
- the glucocorticosteroid starting material for the process suitably has a bioburden of less than 50 CFU (colony forming units) per gram.
- the glucocorticosteroid starting material for the process preferably has a bioburden of less than 10 CFU per gram, more preferably of less than 1 CFU per gram.
- a sterile glucocorticosteroid e.g. budesonide
- a sterile glucocorticosteroid suitably dry and preferably in the form of finely divided particles, e.g. having a mass median diameter of less than 10 ⁇ m, and more preferably less than 5 ⁇ m.
- sterile we mean a product which meets the criteria of sterility according to the US Pharmacopoeia 23/NF18, 1995, pp. 1686-1690 and 1963-1975 and which provides a therapeutically acceptable glucocorticosteroid and formulations thereof.
- Further regulations for sterility of the final product include the European Pharmacopoeia (Ph. Eur. 1998, Chapters 2.6.1 and 5.1.1), the British Pharmacopoeia (BP 1993, Appendix XVI A. p. A180 and Appendix XVIII A, p. A184) and the Japanese Pharmacopoeia (JP, 13 th ed., pp. 69-71 and 181-182).
- the therapeutically acceptable glucocorticosteroid and formulation thereof have been produced by a method which provides assurance of sterility according to the US Pharmacopoeia 23/NF18, 1995, pp. 1686-1690 and 1963-1975.
- the glucocorticosteroid according to the invention will essentially maintain the same pharmacological activity and physico-chemical properties/its chemical purity and physical form as the starting material from which it is prepared, i.e. the degradation, and especially the chemical degradation, caused by the present sterilization process will be limited.
- the glucocorticosteroid according to the invention is preferably at least 98.5% by weight pure, more preferably at least 99% by weight pure, and most preferably at least 99.2% by weight pure.
- the invention further provides a sterile glucocorticosteroid, preferably an anti-inflammatory glucocorticosteroid, more preferably budesonide, rofleponide or rofleponide palmitate, and most preferably budesonide, for use in the treatment of an allergic and/or inflammatory condition of the nose or lungs, e.g. chronic obstructive pulmonary disease (COPD), rhinitis or asthma.
- COPD chronic obstructive pulmonary disease
- the invention also provides the use of such a sterile glucocorticosteroid, preferably an anti-inflammatory glucocorticosteroid, more preferably budesonide, in the manufacture of a medicament (preferably a sterile medicament) for use in the treatment of such conditions.
- a sterile pharmaceutical formulation comprising a glucocorticosteroid in an aqueous suspension, wherein the glucocorticosteroid is preferably a sterile finely divided glucocorticosteroid, such as budesonide.
- a sterile pharmaceutical formulation comprising a glucocorticosteroid and one or more pharmaceutically acceptable additives, diluents or carries.
- additives include surfactants, pH regulating agents, chelating agents, agents rendering the suspension isotonic and thickening agents.
- a surfactant may be used, optionally in combination with e.g. lecithin.
- the surfactants may also function as stabilizing agents in the formulations according to the present invention
- suitable surfactants include non-ionic surfactants of the alkyl aryl polyether alcohol type, specifically TyloxapolTM—a polymer of 4-(1,1,3,3-tetramethylbutyl)phenol with ethylene oxide and formaldehyde.
- suitable surfactants include sorbitan derivatives, e.g.
- polyoxyethylene sorbitan fatty acid esters preferably of the Polysorbate or TweenTM groups, more preferably polysorbate 80 or polyoxyethylene 20 sorbitan mono-oleate (Tween TM 80).
- Suitable surfactants also include polyoxyethylene ethers, especially polyoxyethylene alkyl ethers, preferably pentaethyleneglycol mono n-dodecylether or C 12 E 5 .
- Further suitable surfactants include poloxamers, polyoxyethylene castor oil derivatives, polyvinylalcohol and block copolymers of polyethyleneoxides, polypropyleneoxides, polybutyleneoxides and polyethyleneglycols (PEGs) or mixtures of any of these.
- Further suitable surfactants include polyethylene glycol derivatives, especially polyethylene glycol 660 hydroxystearate or SolutolTM HS 15, povidone, polyvinylpyrrolidone (PVP) and polyethyleneglycols (PEGs).
- the surfactant may be present at about 0.0002 to 2% w/w of the formulation.
- the pH of the suspension may be adjusted as required.
- suitable pH regulating agents are weak organic acids, e.g. citric acid, strong mineral acids, e.g. hydrochloric acid, and strong alkaline agents, e.g. NaOH.
- the pH of the system can be adjusted by balancing the acid and salt forms of buffers such as citric acid, sodium citrate, acetic acid, sodium acetate and sodium phosphate.
- the formulation may also contain a suitable chelating agent, e.g. disodium edetate (EDTA).
- EDTA disodium edetate
- the chelating agent may be present at about 0.005 to 0.1% w/w of the formulation.
- Agents which make the suspension isotonic may be added. Examples are dextrose, glycerol, mannitol, sodium chloride, potassium chloride and sodium bromide.
- a thickening agent may be included in the formulation.
- suitable thickening agents are cellulose derivatives, suitably cellulose ethers, or microcrystalline cellulose.
- Preferred cellulose ethers include ethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, ethylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and carboxymethylecellulose (CMC), e.g. the sodium salt thereof.
- Suitable thickening agents also include cyclodextrin and dextrin.
- Suitable thickening agents further include xanthan gum, guar gum and carbomer.
- Preferred thickening agents in the formulations of the invention are povidone, polyvinylpyrrolidone (PVP) and polyethyleneglycols (PEGs).
- the thickening agent may be present at about 0.1 to 3.0% w/w of the formulation.
- microcrystalline cellulose and sodium carboxymethyl cellulose (CMC) are present at about 0.5 to 2.5%, xanthan gum at about 0.3 to 3%, carbomer at about 0.1 to 2%, guar gum at about 0.3 to 2% and hydroxypropyl methyl cellulose at about 0.5 to 3.0%, w/w of the formulation.
- the suspension that active constituent, e.g. budesonide, is present as small particles, where at least 90% of the small particles have a mass median diameter (MMD) of less than 20 ⁇ m, suitably at least 80% less than 10 ⁇ m, preferably at least 70% less than 7 ⁇ m and most preferably at least 60% less than 4 ⁇ m.
- MMD mass median diameter
- the suspension to contain from about 0.05 to about 20 mg/ml of glucocortiosteroid. More preferably the suspension contains from 0.08 to 10 mg/ml of the glucocorticosteroid and most preferably from 0.1 to 5 mg/ml of the glucocorticosteroid.
- a sterile pharmaceutical formulation comprising a glucocorticosteroid, such as finely divided budesonide, rofleponide or rofleponide palmitate, sterilized according to the present process, can be prepared by mixing the sterilized glucocorticosteroid with any suitable additional ingredient, e.g. a surfactant, a pH regulating or chelating agent, an agent rendering the suspension isotonic or a thickening agent. All components, other than the glucocorticosteroid, can be produced by sterile filtration of their aqueous solutions.
- the resulting sterile suspension may be stored under an over pressure of a sterile and inert gas, e.g. nitrogen or argon, and should be filled under aseptic conditions into pre-sterilized containers to produce a sterile pharmaceutical product, e.g. using a blow/fill/seal system.
- the invention further provides a method for treatment of an inflammatory condition of the nose or lungs by administering to a mammal, especially a human being, suffering from such a condition a therapeutically effective amount of a sterile glucocorticosteroid or a sterile formulation containing a glucocorticosteroid, preferably a sterile formulation containing a sterile glucocorticosteroid produced according to the present invention.
- the invention provides a method for treatment of chronic obstructive pulmonary disease (COPD), rhinitis, asthma or other allergic and/or inflammatory conditions by administering to a mammal, especially a human being, suffering from such a condition a therapeutically effective amount of a sterile glucocorticosteroid or a sterile formulation containing a glucocorticosteroid, preferably a sterile formulation containing a sterile glucocorticosteroid produced according to the present invention.
- COPD chronic obstructive pulmonary disease
- rhinitis asthma or other allergic and/or inflammatory conditions
- sample nos. 2-10 in Table 1 below were subjected to the heat treatment shown in Table 1 in a dry sterilizer, Lytzen model CB 1200. Sample 1 was not subjected to such treatment and was used as the reference sample. After the treatment the samples were analyzed for chemical and physical properties. TABLE 1 No. 1 2 3 4 5 6 7 8 9 10 Temp/° C.
- BET Brunauer, Emett and Teller
- the sterilization of budesonide was compared with that of calcium stearate.
- Tests were performed to evaluate the heat resistance of various naturally occurring microorganisms.
- All the components, other than the budesonide, were produced by sterile filtration of their aqueous solutions and an appropriate volume of the resulting suspension (about 2 ml) was filled under aseptic conditions into pre-sterilized 5 ml containers to produce a sterile product.
- the resulting suspension may be stored under an over-pressure of sterile nitrogen and may be filled into containers using a blow/fill/seal system.
- a sterile formulation comprising finely divided budesonide sterilized by the method of Example 2, can be prepared by mixing the following ingredients: TABLE 5 Micronized budesonide 2-3 mg Disodium edetate 0.1 mg Sodium chloride 8.5 mg Stabilizing agent 0.02-2 mg Anhydrous citric acid 0.28 mg Sodium citrate 0.5 mg Purified water to 1 ml
- All the components, other than the budesonide, can be produced by sterile filtration of their aqueous solutions and an appropriate volume of the resulting suspension (about 2 ml) filled under aseptic conditions into pre-sterilized 5 ml containers to produce a sterile product.
- the resulting suspension may be stored under an over-pressure of sterile nitrogen and may be filled into containers using a blow/fill/seal system.
- the substance and the spore suspension were mixed and dried for approximately 3 hours at 55° C.
- the inoculated and dried budesonide was mixed with 20-40 g of non-inoculated micronized budesonide.
- the number of spores before heat treatment were determined in samples heated at 80° C. for 10 min in order to kill the vegetative cells.
- the samples were heat treated at 110° C. A sample was withdrawn after various heating times. The number of spores/g were determined by a pour plate technique according to US Pharmacopoeia 23/NF18, 1995, pp. 1681-1686, especially p. 1684.
- Table 7 clearly shows that the present process is very efficient in reducing the number of spores in samples containing glucocorticosteroids.
- the process is especially efficient with budesonide and rofleponide.
- budesonide and rofleponide yielded total kill at very short cycle times ( ⁇ 5 minutes at 110° C.), where a D 110 value could not be calculated.
- micronized budesonide substance stored in a plastic container, were subjected to irradiation. The substance was exposed to ⁇ -irradiation at 2.5 to 25 kGy and ⁇ -irradiation at 8 to 32 kGy. After the exposure the budesonide content and the amount of related substances were determined by liquid chromatography. The chemical stability of budesonide was considered to be the most critical parameter to study. TABLE 8 Stability of micronized budesonide substance during sterilization by irradiation Exposure Ref.
- micronized budesonide can not be satisfactorily sterilized with ⁇ - or ⁇ -irradiation, due to significant chemical degradation.
Abstract
The invention provides a process for the sterilization of a powdered form of a glucocorticosteroid, sterile glucocorticosteroids, sterile formulations containing glucocorticosteroids and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or lungs.
Description
- This invention relates to a process for sterilization of a powdered form of a glucocorticosteroid, sterile glucocorticosteroids, sterile formulations containing glucocorticosteroids and use thereof in the treatment of an allergic and/or inflammatory condition of the nose or lungs.
- Various methods have been proposed in the past for the sterilization of glucocorticosteroids. PT-A-69652 discloses the cold sterilization of micronized glucocorticosteroids using mixtures of ethylene oxide and carbon dioxide, since, according to PT-A-69652, steroids in powder form are not stable at temperatures above 60° C. Specific examples of glucorticorsteroids are prednacindone, dexamethasone and prednisolone, and salts, esters and fluoro derivatives thereof, including dexamethasone acetate, dexamethasone phosphate, prednisolone pivalate and 9-alphafluoro prednisolone. However, ethylene oxide is toxic and when it is used to sterilize glucocorticosteroids it has been found that the residual amounts of the ethylene oxide contravene pharmaceutical guidelines which require very low levels of residual ethylene oxide. Accordingly this method has been found to be unsuitable for producing therapeutically acceptable glucocorticosteroids and formulations thereof.
- U.S. Pat. No. 3,962,430 discloses a method for the production of sterile isotonic solutions of medicinal agents, which comprises adding the agent to a saturated solution of sodium chloride in water at 100° C. and then heating the mixture at 100-130° C. This method is not suitable for suspensions of fine particles of glucocorticosteroids which are intended for inhalation because the water, and the heating and cooling involved, produce unfavorable changes in the size of the particles. Indeed it can lead to the formation of bridges between the fine particles producing large, hard aggregates which will not deaggregate into the desired fine particles upon administration.
- A putative alternative is dry heat sterilization. According to the European Pharmacopoeia (1996, pp. 283-4) a normal heat sterilization process runs at 180° C. for 30 min or at a minimum of 160° C. for at least 2 hours. According to Pharmacopoeia Nordica (1964, pp. 16) such a sterilization can be carried out at 140° C. for 3 hours. However at the temperatures of these processes glucocorticosteroids suffer significant degradation and are subject to changes in their surface structure.
- Sterilization by β- or γ-irradiation is also known. Indeed Illum and Moeller in Arch. Pharm. Chemi. Sci., Ed. 2, 1974, pp. 167-174 recommend the use of such irradiation to sterilize glucocorticosteroids. However when such irradiation is used to sterilize certain finely divided, e.g. micronized, glucocorticosteroids, they are significantly degraded.
- WO-A-96/09814 to Andaris Ltd. relates to spray-dried particles of a water-soluble material with a mass median particle size of 1 to 10 μm. The aim of the invention is to produce uniform and reproducible particles for use in dry powder inhalers. The water-soluble material is preferably a human protein or a fragment thereof, in natural or recombinant form, e.g. human serum albumin (HSA), alpha-1 antitrypsin or alcohol dehydrogenase. Also combinations of an active material with a carrier were produced e.g. budesonide and lactose. It is stated generally that the microparticles produced can be sterile without teaching now this could or would be achieved nor showing any proof thereof.
- WO-A-96/32905 to Astra AB relates to a process for the preparation of respirable particles by dissolving an inhalation compound in a solvent, introducing the resulting solution containing the inhalation compound in droplet form or as a jet stream into an anti-solvent which is miscible with the solvent and which is under agitation. Budesonide with a mass median diameter (MMD) of less than 10 μm is produced with the process. There is no information in WO-A-96/32095 about sterilization or sterile particles.
- WO-A-92/11280 to Instytut Farmaceutyczny relates to a method of obtaining (22R) diasteroisomer of budesonide by a condensation reaction followed by crystallizing the crude product of condensaton from ethanol. The obtained 21-acetate of budesonide (22R) is hydrolyzed and the product thus obtained is crystallized from ethyl acetate. The content of (22S) diasteroisomer of budesonide is 1% or less. There is no information in WO-A-92/11280 about sterilization or sterile particles.
- We have also found that attempts at terminal sterilization of the pharmaceutical formulations, especially suspensions, e.g. aqueous suspensions, of glucocorticosteroids have all proved unsatisfactory. Such suspensions can not normally be sterilized by sterile filtration as most of the particles of glucocorticosteroid will be retained on the filter. We have also shown that moist heat sterilization, e.g. steam treatment of glass vials containing the product, leads to an unacceptable change in particle size.
- Various aqueous suspensions of finely divided glucocorticosteroids are known, e.g. the budesonide-containing product known as Pulmicort® nebulising suspension. (Pulmicort® is a trademark of Astra AB of Sweden). Similar formulations of fluticasone propionate are known from WO-A-95/31964.
- According a new process for the sterilization of glucocorticosteroids (and formulations containing them) is required.
- Surprisingly we have now found that effective sterilization of dry glucocorticosteroids can be carried out at a signficantly lower temperature than that considered necessary for the heat sterilization of other substances. Such sterile glucocorticosteroids can be used in the preparation of sterile formulations containing them.
- According to the invention there is provided a process for the sterilization of a glucocorticosteroid, which process comprises heat treating the glucocorticosteroid in the form of a powder at a temperature of from 100 to 130° C. The process is preferably carried out at a temperature of from 110 to 120° C., more preferably at about 110° C., preferably for up to about 24 hours, more preferable up to 10 hours, e.g. from 1 to 10 hours. The process is conveniently carried out under atmospheric conditions, i.e. in air, but may also be carried out under an inert gas atmosphere, e.g. an atmosphere of argon or nitrogen.
- Surprisingly we have found that this process kills many more spores when applied to the glucocorticosteroid budesonide than when applied to the comparison substance calcium stearate. Even better results were obtained with the glucocorticosteroid rofleponide.
- It is believed, but we do not intend to be limited by this explanation, that the unexpectedly low temperature at which the glucocorticosteroids can be sterilized indicates that the glucocorticosteroid may provide some synergistic effect, when taken together with the heat treatment, in destroying the spores.
- The glucocorticosteroid used in the invention is preferably an anti-inflammatory glucocorticosteroid, e.g. for use in nasal and oral inhalation. Examples of glucocorticosteroids which may be used in the present invention include betamethasone, fluticasone (e.g. as propionate), budesonide, tipredane, dexamethasone, beclomethasone (e.g. as dipropionate), prednisolone, fluocinolone, triamcinolone (e.g. as acetonide), momethasone (e.g. as furoate), rofleponide (e.g. as palmitate), flumethasone, flunisolide, ciclesonide, deflazacort, cortivazol, 16α, 17α-butylidenedioxy-6α,9α-difluoro-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione; 6α, 9α-difluoro-11β-hydroxy-16α, 17α-butylidenedioxy-17β-methylthioandrosta-4-ene-3-one; 16α,17α- butylidenedioxy-6α,9α-difluoro-11β-hydroxy-3oxoandrosta-1,4-diene-17β-carbothioic acid S-methyl ester; methyl 9α-chloro-6α-chloro-6α-fluoro-11β-hydroxy-16α-methyl -3oxo-17α-propionyloxy-androsta-1,4-diene-17αcarboxylate; 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxy-androsta-1,4-diene-17β-carbothioic acid S-(2-oxo-tetrahydrofuran-3-yl) ester; optionally in their pure isomeric forms (where such forms exist) and/or in the form of their esters, acetals or salts, where applicable. Suitably, use is made of momethasone furoate, beclomethasone dipropionate or fluticasone propionate or glucocorticosteroids with an asymmetric acetal structure, i.e. comprising 16α,17α-butylidenedioxy, such as budesonide, rofleponide or rofleponide palmitate. Preferably, use is made of budesonide, rofleponide or rofleponide palmitate and most preferably of budesonide.
- The glucocorticosteroid is preferably used in the form of a finely divided, e.g. micronized, powder, particularly in the form of finely divided particles having a mass median diameter of less than 10 μm, more preferably less than 5 μm. The glucocorticosteroid may alternatively be in an ultra fine form, e.g. having a mass median diameter of less than 1.0 μm. The finely divided particles may be produced by conventional techniques known per se. e.g. by micronization or by direct precipitation. Information about micronization can be found e.g. in “The Theory and Practice of Industrial Pharmacy”, Lachman, Liebermann and Klang, 2nd Ed., 1976, Lea & Febiger, Philadelphia, USA.
- The temperature, time, batch size and type of sterilizer used will be interdependent. Thus generally the higher the temperature used in the process according to the invention, the less time is required to sterilize the glucocorticosteroid. The process is preferably carried out for no more than 8 hours, e.g. from 1 to 8 hours, when the temperature is greater than about 110° C., more preferably no more than 4 hours. At a temperature of about 120° C. the process is preferably carried out for no more than 4 hours, e.g. from 1 to 4 hours, more preferably no more than 2 hours, e.g. from 1 to 2 hours.
- At temperatures of from about 110° C. up to 130° C., a batch of 50 g of glucocorticosteroid may suitably be heat treated from 1 to 4 hours. If desired sub-batches, e.g. of 4×50 g, may be used.
- The present process may be carried out such that it results in a more than log 4 reduction in the amount of heat resistant spores. The process of the present invention is suitably carried out such that it results in a log 6 reduction in the amount of heat resistant spores. The present process is preferably carried out such that it results in a more than log 6 reduction, and more preferably such that it results in a more than log 7 reduction in the amount of heat resistant spores.
- A different way of characterizing the efficiency of a sterilizing process is by using the D value. The D value, also known as the DT value, is the time (in minutes) required to reduce (“kill”) a standardized population of spores by 90% or 1 log cycle, i.e. to a survival fraction of 1/10, at a specific temperature T (in °C.).
- The present process may be carried out such that the D value is less than about 240 min at the preselected temperature T, wherein T is in the range of from 100 to 130° C. The process of the present invention is suitably carried out such that the D value is less than 150 min at the preselected temperature T. Preferably, the process of the present invention is carried out such that the D value is less than 90 min at the preselected temperature T, and more preferably such that the D value is less than 30 min at the preselected temperature T. T is suitably 100, 110, 120 or 130° C.
- The sterilization process is desirably carried out in such a manner that all parts of the bulk of the glucocorticosteroid reaches, and is maintained within, the desired temperature for the desired time.
- The present process may be carried out batch wise or continuously, preferably batch wise.
- The glucocorticosteroid starting material for the process, which material may be in finely divided form, is suitably substantially dry, i.e. containing less than about 1% (w/w) of water. Preferably, the starting material for the process contains less than 0.5% (w/w) of water, and more preferably less than 0.3% (w/w) of water.
- The glucocorticosteroid starting material for the process suitably has a bioburden of less than 50 CFU (colony forming units) per gram. The glucocorticosteroid starting material for the process preferably has a bioburden of less than 10 CFU per gram, more preferably of less than 1 CFU per gram.
- According to the invention there is further provided a sterile glucocorticosteroid (e.g. budesonide), suitably dry and preferably in the form of finely divided particles, e.g. having a mass median diameter of less than 10 μm, and more preferably less than 5 μm.
- By the term “sterile” we mean a product which meets the criteria of sterility according to the US Pharmacopoeia 23/NF18, 1995, pp. 1686-1690 and 1963-1975 and which provides a therapeutically acceptable glucocorticosteroid and formulations thereof. Further regulations for sterility of the final product include the European Pharmacopoeia (Ph. Eur. 1998, Chapters 2.6.1 and 5.1.1), the British Pharmacopoeia (BP 1993, Appendix XVI A. p. A180 and Appendix XVIII A, p. A184) and the Japanese Pharmacopoeia (JP, 13th ed., pp. 69-71 and 181-182). Preferably, the therapeutically acceptable glucocorticosteroid and formulation thereof have been produced by a method which provides assurance of sterility according to the US Pharmacopoeia 23/NF18, 1995, pp. 1686-1690 and 1963-1975.
- The glucocorticosteroid according to the invention will essentially maintain the same pharmacological activity and physico-chemical properties/its chemical purity and physical form as the starting material from which it is prepared, i.e. the degradation, and especially the chemical degradation, caused by the present sterilization process will be limited.
- The glucocorticosteroid according to the invention is preferably at least 98.5% by weight pure, more preferably at least 99% by weight pure, and most preferably at least 99.2% by weight pure.
- The invention further provides a sterile glucocorticosteroid, preferably an anti-inflammatory glucocorticosteroid, more preferably budesonide, rofleponide or rofleponide palmitate, and most preferably budesonide, for use in the treatment of an allergic and/or inflammatory condition of the nose or lungs, e.g. chronic obstructive pulmonary disease (COPD), rhinitis or asthma. The invention also provides the use of such a sterile glucocorticosteroid, preferably an anti-inflammatory glucocorticosteroid, more preferably budesonide, in the manufacture of a medicament (preferably a sterile medicament) for use in the treatment of such conditions.
- According to the invention there is further provided a sterile pharmaceutical formulation comprising a glucocorticosteroid in an aqueous suspension, wherein the glucocorticosteroid is preferably a sterile finely divided glucocorticosteroid, such as budesonide.
- According to the invention there is also provided a sterile pharmaceutical formulation comprising a glucocorticosteroid and one or more pharmaceutically acceptable additives, diluents or carries. Examples of such additives include surfactants, pH regulating agents, chelating agents, agents rendering the suspension isotonic and thickening agents.
- To obtain an efficient dispersion of the glucocorticosteroid particles in the suspension, a surfactant may be used, optionally in combination with e.g. lecithin. The surfactants may also function as stabilizing agents in the formulations according to the present invention Examples of suitable surfactants include non-ionic surfactants of the alkyl aryl polyether alcohol type, specifically Tyloxapol™—a polymer of 4-(1,1,3,3-tetramethylbutyl)phenol with ethylene oxide and formaldehyde. Further suitable surfactants include sorbitan derivatives, e.g. polyoxyethylene sorbitan fatty acid esters, preferably of the Polysorbate or Tween™ groups, more preferably polysorbate 80 or polyoxyethylene 20 sorbitan mono-oleate (Tween ™ 80). Suitable surfactants also include polyoxyethylene ethers, especially polyoxyethylene alkyl ethers, preferably pentaethyleneglycol mono n-dodecylether or C12E5. Further suitable surfactants include poloxamers, polyoxyethylene castor oil derivatives, polyvinylalcohol and block copolymers of polyethyleneoxides, polypropyleneoxides, polybutyleneoxides and polyethyleneglycols (PEGs) or mixtures of any of these. Further suitable surfactants include polyethylene glycol derivatives, especially polyethylene glycol 660 hydroxystearate or Solutol™ HS 15, povidone, polyvinylpyrrolidone (PVP) and polyethyleneglycols (PEGs).
- The surfactant may be present at about 0.0002 to 2% w/w of the formulation. We prefer the polyoxyethylene sorbitan fatty acid esters to be present at about 0.005 to 0.5% w/w, poloxamers at about 0.01 to 2% w/w, and polyoxyethylene alkyl ethers of the polyoxyethylene castor oil derivatives at about 0.01 to 1.0% w/w of the formulation.
- The pH of the suspension may be adjusted as required. Examples of suitable pH regulating agents are weak organic acids, e.g. citric acid, strong mineral acids, e.g. hydrochloric acid, and strong alkaline agents, e.g. NaOH. Alternatively, the pH of the system can be adjusted by balancing the acid and salt forms of buffers such as citric acid, sodium citrate, acetic acid, sodium acetate and sodium phosphate. We prefer the formulations intended for inhalation to have a pH in the range of from about 3.5 to about 6.0, more preferably from 4.0 to 5.0, and most preferably from 4.2 to 4.8.
- We also prefer the formulation to contain a suitable chelating agent, e.g. disodium edetate (EDTA). The chelating agent may be present at about 0.005 to 0.1% w/w of the formulation.
- Agents which make the suspension isotonic may be added. Examples are dextrose, glycerol, mannitol, sodium chloride, potassium chloride and sodium bromide.
- In order to form a stable suspension with a minimal tendency to agglomerate of form a sediment, a thickening agent may be included in the formulation. Examples of suitable thickening agents are cellulose derivatives, suitably cellulose ethers, or microcrystalline cellulose. Preferred cellulose ethers include ethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, ethylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and carboxymethylecellulose (CMC), e.g. the sodium salt thereof. Suitable thickening agents also include cyclodextrin and dextrin. Suitable thickening agents further include xanthan gum, guar gum and carbomer. Preferred thickening agents in the formulations of the invention are povidone, polyvinylpyrrolidone (PVP) and polyethyleneglycols (PEGs).
- The thickening agent may be present at about 0.1 to 3.0% w/w of the formulation. Preferably microcrystalline cellulose and sodium carboxymethyl cellulose (CMC) are present at about 0.5 to 2.5%, xanthan gum at about 0.3 to 3%, carbomer at about 0.1 to 2%, guar gum at about 0.3 to 2% and hydroxypropyl methyl cellulose at about 0.5 to 3.0%, w/w of the formulation.
- In the suspension that active constituent, e.g. budesonide, is present as small particles, where at least 90% of the small particles have a mass median diameter (MMD) of less than 20 μm, suitably at least 80% less than 10 μm, preferably at least 70% less than 7 μm and most preferably at least 60% less than 4 μm.
- We prefer the suspension to contain from about 0.05 to about 20 mg/ml of glucocortiosteroid. More preferably the suspension contains from 0.08 to 10 mg/ml of the glucocorticosteroid and most preferably from 0.1 to 5 mg/ml of the glucocorticosteroid.
- A sterile pharmaceutical formulation comprising a glucocorticosteroid, such as finely divided budesonide, rofleponide or rofleponide palmitate, sterilized according to the present process, can be prepared by mixing the sterilized glucocorticosteroid with any suitable additional ingredient, e.g. a surfactant, a pH regulating or chelating agent, an agent rendering the suspension isotonic or a thickening agent. All components, other than the glucocorticosteroid, can be produced by sterile filtration of their aqueous solutions. The resulting sterile suspension may be stored under an over pressure of a sterile and inert gas, e.g. nitrogen or argon, and should be filled under aseptic conditions into pre-sterilized containers to produce a sterile pharmaceutical product, e.g. using a blow/fill/seal system.
- The invention further provides a method for treatment of an inflammatory condition of the nose or lungs by administering to a mammal, especially a human being, suffering from such a condition a therapeutically effective amount of a sterile glucocorticosteroid or a sterile formulation containing a glucocorticosteroid, preferably a sterile formulation containing a sterile glucocorticosteroid produced according to the present invention. More specifically, the invention provides a method for treatment of chronic obstructive pulmonary disease (COPD), rhinitis, asthma or other allergic and/or inflammatory conditions by administering to a mammal, especially a human being, suffering from such a condition a therapeutically effective amount of a sterile glucocorticosteroid or a sterile formulation containing a glucocorticosteroid, preferably a sterile formulation containing a sterile glucocorticosteroid produced according to the present invention.
- The invention is illustrated by reference to the following Examples which are not intended to limit the invention.
- Experiments were carried out to determine the effect of heat treatment upon the chemical purity and physical form of samples of micronized budesonide.
- Nine 50 g batches of micronized budesonide (sample nos. 2-10 in Table 1 below) were subjected to the heat treatment shown in Table 1 in a dry sterilizer, Lytzen model CB 1200. Sample 1 was not subjected to such treatment and was used as the reference sample. After the treatment the samples were analyzed for chemical and physical properties.
TABLE 1 No. 1 2 3 4 5 6 7 8 9 10 Temp/° C. — 100 100 100 110 110 110 120 120 120 Time/hours 0 4 6 10 2 4 10 1 2 4 Size/μm 2.0 2.2 2.2 2.2 2.2 2.2 2.3 2.2 2.2 2.3 Size range (10- 2.6 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 90%)/μm Epimer A/% by wt 48.8 48.8 48.7 48.7 48.7 48.8 48.7 48.7 48.7 48.7 Budesonide 99.4 99.3 99.3 99.2 99.2 99.3 98.9 99.2 99.2 99.0 content/% by wt Total of known 0.13 0.14 0.16 0.15 0.16 0.15 0.18 0.14 0.15 0.17 foreign steroids Total of unknown 0.04 0.04 0.05 0.05 0.04 0.08 0.18 0.04 0.07 0.16 - After the heat treatment there was no change in the Brunauer, Emett and Teller (BET) surface value (as measured using a Micrometrics Gemini 2375 device; see also British Standard 4359 (1969)part 1) of the budesonide or in its X-ray diffraction pattern for each sample compared to sample 1. The size for each sample was measured as the mass median diameter (MMD) using a Coulter counter.
- The sterilization of budesonide was compared with that of calcium stearate.
- Samples of 0.5 g of budesonide and of 0.5 g of calcium stearate were each inoculated with 0.1 ml of a Steris Bacillus subtilis (globigii) (Lot# LG126B) spore suspension containing 1.5×107 spores. Each sample was subjected to a temperature of 110° C. for 3 hours and 10 min in a Baxter Constant Temperature Oven using the same technique as in Example 1. The spore population of the samples was measured and the results obtained are shown below in Table 2.
TABLE 2 Compound Before After Calcium stearate 1.5 × 107 spores 3.3 × 106 spores Budesonide 1.5 × 107 spores <10 spores - As a result of the heat treatment, a spore log reduction of greater than 6.2 was obtained in the inoculated sample of budesonide, whereas the log reduction was less than 0.7 in the inoculated sample of calcium stearate.
- Tests were performed to evaluate the heat resistance of various naturally occurring microorganisms.
- Samples of 0.5 g of budesonide powder were each inoculated with approximately 102-103 viable ATCC microorganisms in 120 ml open-ended polypropylene container. Each sample was subjected to a temperature of 110° C. for 3 hours and 10 min. The microorganism population of the samples was measured before and after heat treatment and the results obtained are shown below in Table 3.
TABLE 3 Microorganism Before After E. coli 450 0 B. subtilis ATCC 6633 300 0 Salmonella typhi 270 0 C. albicans 780 0 A. niger 260 0 M. luteus 300 0 S. epidermidis 240 0 C. sporogenes 160 0 Ps. Aeruginosa 350 0 B. subtilis ATCC 6633 1.2 × 105 11
1A singular bacillus species was found, verified by Gram stain in the 100 dilution plate.
- As is evident from Table 3, heat treatment of budesonide at 110° C. for 3 hours and 10 min, is an effective sterilizing method for a substantial variety of microorganisms.
- A formulation comprising finely divided budesonide sterilized by the method of Example 2, and meeting the criteria of sterility according to the US Pharmacopoeia 23/NF18, 1995, was prepared by mixing the following ingredients:
TABLE 4 Micronized budesonide 0.125 mg Disodium edetate 0.1 mg Sodium chloride 8.5 mg Polysorbate 80 0.2 mg Anhydrous citric acid 0.28 mg Sodium citrate 0.5 mg Purified water to 1 ml - All the components, other than the budesonide, were produced by sterile filtration of their aqueous solutions and an appropriate volume of the resulting suspension (about 2 ml) was filled under aseptic conditions into pre-sterilized 5 ml containers to produce a sterile product.
- The resulting suspension may be stored under an over-pressure of sterile nitrogen and may be filled into containers using a blow/fill/seal system.
- A sterile formulation comprising finely divided budesonide sterilized by the method of Example 2, can be prepared by mixing the following ingredients:
TABLE 5 Micronized budesonide 2-3 mg Disodium edetate 0.1 mg Sodium chloride 8.5 mg Stabilizing agent 0.02-2 mg Anhydrous citric acid 0.28 mg Sodium citrate 0.5 mg Purified water to 1 ml - All the components, other than the budesonide, can be produced by sterile filtration of their aqueous solutions and an appropriate volume of the resulting suspension (about 2 ml) filled under aseptic conditions into pre-sterilized 5 ml containers to produce a sterile product.
- The resulting suspension may be stored under an over-pressure of sterile nitrogen and may be filled into containers using a blow/fill/seal system.
- 5 g of micronized budesonide was inoculated with approximately 2 ml of a spore suspension of Bacillus subtilis.
- The substance and the spore suspension were mixed and dried for approximately 3 hours at 55° C. The inoculated and dried budesonide was mixed with 20-40 g of non-inoculated micronized budesonide.
- 5 g portions of this sample were heat treated at 100° C., 110° C. in a Heraeus ST 5060 heating apparatus. A 1 g sample was withdrawn after various heating times at the respective heating temperatures. Each such 1 g sample was transferred to 10 ml of dilution medium pH 7.2. Appropriate dilutions were made in 0.1% Peptone Aqueous solution and the number of spores/g were determined by a pour plate technique according to US Pharmacopoeia 23/NF18. 1995, pp. 1681-1686, especially p. 1684.
- The number of spores before heat treatment were determined in samples heated at 80° C. for 10 min in order to kill the vegetative cells.
- The results are shown in Table 6, where the DT value is the amount of time in minutes required to obtain a log 1 reduction in the number of spores before and after heat treatment at the temperature T (in ° C.).
TABLE 6 Heating at 100° C. 80° C. Heating time at 100° C. 10 min 15 min 45 min 75 min spores/g 6.5 × 106 4.8 × 103 7.1 × 102 1.7 × 102 log spores/g 6.81 3.68 2.85 2.23 D100 = 41.5 min; correlation coefficient = −0.0996 This means that it takes 6 × 41.5 minutes to obtain a log 6 reduction in the number of spores at a temperature of 100° C. Heating at 110° C. 80° C. Heating time at 110° C. 10 min 5 min 15 min 20 min spores/g 2 × 106 2.08 × 104 9.25 × 102 3.55 × 102 log spores/g 6.20 4.32 2.97 2.55 D110 = 8.3 min; correlation coefficient = −0.995 This means that it takes 6 × 8.3 minutes to obtain a log 6 reduction in the number of spores at a temperature of 110° C. Heating at 120° C. 80° C. Heating time at 120° C. 10 min 4 min 6 min 8 min spores/g 1.5 × 106 1.9 × 102 5.5 × 101 2 × 101 log spores/g 6.19 2.28 1.74 1.30 D120 = 4.1 min; correlation coefficient = −0.998 This means that it takes 6 × 4.1 minutes to obtain a log 6 reduction in the number of spores at a temperature of 120° C. - 1 g of micronized budesonide, prednisolone and beclomethasone dipropionate and 0.5 g of rofleponide were inoculated with a different spore suspension to the one used in Example 6.
- The samples were heat treated at 110° C. A sample was withdrawn after various heating times. The number of spores/g were determined by a pour plate technique according to US Pharmacopoeia 23/NF18, 1995, pp. 1681-1686, especially p. 1684.
- From the number of spores before and after heat treatment the log reduction of spores and decimal reduction time (time needed at a specified temperature to reduce the number of microorganisms with one log) was calculated.
- The results are shown in Table 7.
TABLE 7 Heating at 110° C. Glucocorticosteroid D110 value in min Budesonide 41 Rofleponide 9.8 Beclomethasone dipropionate 72.7 Prednisolone 73.8 - Table 7 clearly shows that the present process is very efficient in reducing the number of spores in samples containing glucocorticosteroids. The process is especially efficient with budesonide and rofleponide. In fact analysis conducted on a full 1.0 g sample of rofleponide yielded total kill at very short cycle times (≧5 minutes at 110° C.), where a D110 value could not be calculated.
- Irradiation
- About 3 g of micronized budesonide substance stored in a plastic container, were subjected to irradiation. The substance was exposed to β-irradiation at 2.5 to 25 kGy and γ-irradiation at 8 to 32 kGy. After the exposure the budesonide content and the amount of related substances were determined by liquid chromatography. The chemical stability of budesonide was considered to be the most critical parameter to study.
TABLE 8 Stability of micronized budesonide substance during sterilization by irradiation Exposure Ref. β β β β β γ γ Intensity (kGy) 1) 2.5 5 10 17 25 7.8 31.9 Budesonide 99.5- 99.1 98.9 98.9 98.8 98.8 97.9 95.0 content (%) 99.8 Related substances Total of known 0.13- 0.19 0.19 0.18 0.20 0.21 0.34 0.51 foreign steroids 0.15 Total of 0.03- 0.19 0.24 0.26 0.36 0.43 0.68 1.8 unknown 0.04 foreign steroids
1) The analysis was done on different days and the reference was analyzed at all occasions
- From the results in Table 8, it can be seen that the budesonide content decreases in samples exposed to β- and y-irradiation. Several new degradation products were observed, especially for the γ-irradiated sample. In addition the mass balance for both β- and γ-irradiated samples is poor. The budesonide content has decreased by 0.5-4.6 per cent, when exposed to β- or γ-irradiation.
- It can be concluded that micronized budesonide can not be satisfactorily sterilized with β- or γ-irradiation, due to significant chemical degradation.
Claims (51)
1.-31. (canceled)
32. A method of manufacturing a sterile composition, the method comprising
(a) providing a powder composition comprising a glucocorticosteroid or an ester, acetal, or salt thereof, wherein the glucocorticosteroid contains an asymmetric acetal structure comprising 16α,17α-butylidenedioxy; and
(b) sterilizing the powder composition by a method comprising heat sterilization.
33. The method of claim 32 , wherein the heat sterilization comprises heating the powder composition to a temperature in the range of 100 to 130° C.
34. The method of claim 32 , wherein the heat sterilization comprises heating the powder composition to a temperature in the range of 100 to 120° C.
35. The method of claim 32 , wherein the heat sterilization comprises heating the powder composition to a temperature of about 110° C.
36. The method of claim 32 , wherein the glucocorticosteroid is an anti-inflammatory glucocorticosteroid.
37. The method of claim 32 , wherein the glucocorticosteroid or ester, acetal, or salt thereof is selected from the group consisting of budesonide, rofleponide, and rofleponide palmitate.
38. The method of claim 32 , wherein the heat sterilization is performed or no longer than 10 hours.
39. The method of claim 32 , wherein the heat sterilization is carried out in air.
40. The method of claim 63 , wherein the heat sterilization is carried out under an inert gas atmosphere.
41. The method of claim 32 , wherein the heat sterilization comprises a dry-heat treatment.
42. The method of claim 32 , wherein the glucocorticosteroid is budesonide.
43. The method of claim 32 , wherein the glucocorticosteroid is isomerically pure budesonide.
44. The method of claim 43 , wherein the budesonide is in the form of the (22R) diasteroisomer.
45. The method of claim 32 , wherein the powder composition contains less than about 1% (w/w) of water at a point just before the heat sterilization.
46. The method of claim 32 , wherein the powder composition consists of particles having a mass median diameter of less than 10 μm.
47. The method of claim 32 , wherein the powder composition consists of particles having a mass median diameter of less than 5 μm.
48. The method of claim 32 , wherein the number of heat resistant spores in the powder composition is reduced by more than log 6 by the heat sterilization.
49. The method of claim 32 , wherein the number of heat resistant spores in the powder composition is reduced by more than log 7 by the heat sterilization.
50. The method of claim 32 , wherein the heat sterilization comprises heating the powder composition for a time less than 90 minutes and at a temperature in the range of 100 to 130° C.
51. A method of manufacturing a sterile composition, comprising
(a) providing a powder composition comprising particles of budesonide or an ester, acetal or salt thereof, wherein the particles have a mass median diameter of less than 10 μm; and
(b) dry-heating the powder composition at a temperature in the range of 100 to 130° C., thereby producing the sterile powder composition.
52. The method of claim 51 , wherein the temperature is in the range of from 100 to 120° C.
53. The method of claim 51 , wherein the temperature is in the range of about 110° C.
54. The method of claim 51 , wherein the powder composition is dry-heated for no longer than 10 hours.
55. The method of claim 51 , wherein the dry-heating is carried out in air.
56. The method of claim 51 , wherein the dry-heating is carried out under an inert gas atmosphere.
57. The method of claim 51 , wherein the budesonide is isomerically pure.
58. The method of claim 57 , wherein the budesonide is in the form of the (22R) diastereoisomer.
59. The method of claim 51 , wherein the powder composition contains less than about 1% (w/w) of water at a pint just before the dry-heating.
60. The method of claim 51 , wherein the particles of budesonide have a mass median diameter of less than 5 μm.
61. The method of claim 51 , wherein the number of heat resistant spores in the powder composition is reduced by more than log6 by the dry-heating.
62. The method of claim 51 , wherein the amount of heat resistant spores in the powder composition is reduced by more than log7 by the dry heating.
63. A method of manufacturing a sterile composition, the method comprising
(a) manufacturing a powder composition comprising a glucocorticosteroid or an ester, acetal, or salt thereof, wherein the glucocorticosteroid contains an asymmetric acetal structure comprising 16α,17α-butylidenedioxy, and
(b) sterilizing the powder composition by a method comprising heat sterilization.
64. The method of claim 63 , further comprising combining the sterilized powder composition produced in step (b) with a sterile aqueous solution to produce a sterile aqueous suspension of the powder.
65. The method of claim 63 , wherein step (a) comprises micronizing the glucocorticosteroid or ester, acetal, or salt thereof to produce particles having a mass median diameter of less than 10 μm.
66. The method of claim 63 , wherein step (a) comprises micronizing the glucocorticosteroid or ester, acetal, or salt thereof to produce particles having a mass median diameter of less than 5 μm.
67. The method of claim 63 , wherein the heat sterilization comprises heating the powder composition to a temperature in the range of 100 to 130° C.
68. The method of claim 63 , wherein the heat sterilization comprises heating the powder composition to a temperature in the range of 100 to 120° C.
69. The method of claim 63 , wherein the heat sterilization comprises heating the powder composition to a temperature of about 110° C.
70. The method of claim 63 , wherein the glucocorticosteroid is an anti-inflammatory glucocorticosteroid.
71. The method of claim 63 , wherein the glucocorticosteroid or ester, acetal, or salt thereof is selected from the group consisting of budesonide, rofleponide, and rofleponide palmitate.
72. The method of claim 63 , wherein the heat sterilization is performed for no longer than 10 hours.
73. The method of claim 63 , wherein the heat sterilization is carried out in air.
74. The method of claim 63 , wherein the heat sterilization is carried out under an inert gas atmosphere.
75. The method of claim 63 , wherein the heat sterilization comprises a dry-heat treatment.
76. The method of claim 63 , wherein the glucocorticosteroid is budesonide.
77. The method of claim 63 , wherein the glucocorticosteroid is isomerically pure budesonide.
78. The method of claim 77 , wherein the budesonide is in the form of the (22R) diastereoisomer.
79. The method of claim 63 , wherein the powder composition contains less than about 1% (w/w) of water at a point just before the heat sterilization.
80. The method of claim 63 , wherein the number of heat resistant spores in the powder composition is reduced by more than log6 by the heat sterilization.
81. The method of claim 63 , wherein the number of heat resistant spores in the powder composition is reduced by more than log7 by the heat sterilization.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/690,537 US20070197489A1 (en) | 1997-11-14 | 2007-03-23 | Composition of matter |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9704186-7 | 1997-11-14 | ||
SE9704186A SE9704186D0 (en) | 1997-11-14 | 1997-11-14 | New composition of matter |
PCT/SE1998/002039 WO1999025359A1 (en) | 1997-11-14 | 1998-11-11 | New composition of matter |
US09/230,781 US6392036B1 (en) | 1997-11-14 | 1998-11-11 | Dry heat sterilization of a glucocorticosteroid |
US09/993,669 US7524834B2 (en) | 1997-11-14 | 2001-11-27 | Sterile powders, formulations, and methods for producing the same |
US11/690,537 US20070197489A1 (en) | 1997-11-14 | 2007-03-23 | Composition of matter |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/993,669 Continuation US7524834B2 (en) | 1997-11-14 | 2001-11-27 | Sterile powders, formulations, and methods for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070197489A1 true US20070197489A1 (en) | 2007-08-23 |
Family
ID=20408992
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/230,781 Expired - Lifetime US6392036B1 (en) | 1997-11-14 | 1998-11-11 | Dry heat sterilization of a glucocorticosteroid |
US09/993,669 Expired - Fee Related US7524834B2 (en) | 1997-11-14 | 2001-11-27 | Sterile powders, formulations, and methods for producing the same |
US11/690,537 Abandoned US20070197489A1 (en) | 1997-11-14 | 2007-03-23 | Composition of matter |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/230,781 Expired - Lifetime US6392036B1 (en) | 1997-11-14 | 1998-11-11 | Dry heat sterilization of a glucocorticosteroid |
US09/993,669 Expired - Fee Related US7524834B2 (en) | 1997-11-14 | 2001-11-27 | Sterile powders, formulations, and methods for producing the same |
Country Status (24)
Country | Link |
---|---|
US (3) | US6392036B1 (en) |
EP (1) | EP1032396B1 (en) |
JP (2) | JP4598268B2 (en) |
KR (1) | KR100571075B1 (en) |
CN (1) | CN1173702C (en) |
AR (1) | AR013765A1 (en) |
AT (1) | ATE259642T1 (en) |
AU (1) | AU744992B2 (en) |
BR (1) | BR9814118A (en) |
CA (1) | CA2310222C (en) |
DE (1) | DE69821796T2 (en) |
DK (1) | DK1032396T3 (en) |
ES (1) | ES2214749T3 (en) |
HK (1) | HK1030549A1 (en) |
IL (1) | IL136086A (en) |
MY (1) | MY118856A (en) |
NO (1) | NO327391B1 (en) |
NZ (1) | NZ504273A (en) |
PT (1) | PT1032396E (en) |
SA (1) | SA99190966B1 (en) |
SE (1) | SE9704186D0 (en) |
TW (1) | TWI242436B (en) |
WO (1) | WO1999025359A1 (en) |
ZA (1) | ZA9810217B (en) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0810853B1 (en) * | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
SE9704186D0 (en) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
IT1303692B1 (en) * | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION. |
AR026073A1 (en) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | PHARMACEUTICAL COMPOSITION AQUATIC CONTAINING CICLESONIDE |
AR026072A1 (en) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR MUCOSA APPLICATION |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
EP1337279B1 (en) * | 2000-11-24 | 2006-06-21 | Breath Limited | Sterilisation of glucocorticosteriode suspensions |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
GB0130055D0 (en) * | 2001-12-14 | 2002-02-06 | Technology Innovation Ltd | Medicament packaging |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
PT1471887E (en) | 2002-02-04 | 2010-07-16 | Elan Pharma Int Ltd | Nanoparticulate compositions having lysozyme as a surface stabilizer |
EP1476201B1 (en) * | 2002-02-19 | 2008-12-24 | Resolution Chemicals Limited | Solvent-based sterilisation of steroids |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
CN100366256C (en) * | 2002-07-02 | 2008-02-06 | 奥坦纳医药公司 | Ciclesonide-containing sterile aqueous suspension |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
US20040105778A1 (en) * | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
WO2004052374A1 (en) | 2002-12-12 | 2004-06-24 | Altana Pharma Ag | Combination medicament |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
EP1454636A1 (en) * | 2003-03-04 | 2004-09-08 | Dompé S.P.A. | Sterilization of glucocorticoid drug particles for pulmonary delivery |
DE602004028585D1 (en) * | 2003-03-15 | 2010-09-23 | Brin Tech Internat Ltd | Packaging for medicines |
US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
JP2007501683A (en) * | 2003-05-22 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | Sterilization of nanoparticle active substance dispersions by gamma irradiation |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
GB0319500D0 (en) | 2003-08-19 | 2003-09-17 | Resolution Chemicals Ltd | Particle-size reduction apparatus,and use thereof |
PT1670482E (en) | 2003-09-16 | 2014-03-12 | Takeda Gmbh | Use of ciclesonide for the treatment of respiratory diseases |
PE20050941A1 (en) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | AQUEOUS CYCLESOUND SUSPENSIONS FOR MISTING |
ATE446581T1 (en) * | 2004-03-12 | 2009-11-15 | Trinity College Dublin | MAGNETORRESISTIVE MEDIUM |
US7892483B2 (en) * | 2004-03-12 | 2011-02-22 | Cipla Limited | Sterilization process |
US20070134165A1 (en) * | 2004-04-20 | 2007-06-14 | Altana Pharma Ag | Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient |
ITMI20040795A1 (en) * | 2004-04-23 | 2004-07-23 | Eratech S R L | DRY SOLID PHARMACEUTICAL COMPOSITION ON ITS STABLE WATER PREPARATION AND SUSPENSION PROCESS OBTAINED BY ITSELF |
GB0410995D0 (en) | 2004-05-17 | 2004-06-23 | Norton Healthcare Ltd | Heat sterilization of glucocorticosteroids |
ITSA20040012A1 (en) * | 2004-09-07 | 2004-12-07 | Genetec S P A | STERILIZATION PROCESS OF A GLUCOCORTICOSTEROID. |
GB0425266D0 (en) | 2004-11-16 | 2004-12-15 | Norton Healthcare Ltd | Pharmaceutical manufacturing process |
GB0427568D0 (en) | 2004-12-16 | 2005-01-19 | Resolution Chemicals Ltd | Particle-size reduction apparatus, and the use thereof |
EP1782839A1 (en) | 2005-11-03 | 2007-05-09 | Genetic S.p.A. | Sterilization process of Glucocorticosteroid by supercritical CO2 |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20090252801A1 (en) * | 2005-11-29 | 2009-10-08 | Farmbios S.P.A. | Process for the Preparation of Micronised Sterile Steroids |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070166184A1 (en) * | 2006-01-13 | 2007-07-19 | Zimmer Technology, Inc. | Methods for cleaning and sterilizing devices |
US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
CA2642577A1 (en) * | 2006-02-15 | 2007-08-23 | Tika Lakemedel Ab | Methods of manufacturing corticosteroid solutions |
FR2898273B1 (en) * | 2006-03-07 | 2013-11-08 | Merck Generiques | DRY-HEATING STERILIZATION PROCESS OF A POWDER COMPRISING A GLUCOCORTICOSTEROID |
EP2043698A2 (en) * | 2006-07-20 | 2009-04-08 | Sicor, Inc. | Process for the preparation of solid sterile active pharmaceutical ingredient |
CN101265342B (en) * | 2007-03-12 | 2014-04-02 | 广东炜林纳功能材料有限公司 | Composite beta crystal-type nucleater of polypropylene |
CN102226026B (en) * | 2007-03-12 | 2013-12-18 | 广东炜林纳功能材料有限公司 | Compound beta-crystal nucleating agent used for polypropylene |
AU2008323676B2 (en) * | 2007-11-09 | 2014-04-03 | Map Pharmaceuticals, Inc. | Methods for administering corticosteroid formulations |
GB2458403B (en) * | 2007-11-13 | 2010-01-13 | Meritage Pharma Inc | Stabilised corticosteroid compositions |
US20090123390A1 (en) | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Compositions for the treatment of gastrointestinal inflammation |
KR20190026056A (en) * | 2008-04-21 | 2019-03-12 | 오토노미, 인코포레이티드 | Auris formulations for treating otic diseases and conditions |
WO2009139924A2 (en) | 2008-05-14 | 2009-11-19 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
US8648119B2 (en) * | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
AU2009271129B2 (en) * | 2008-07-14 | 2013-10-10 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
US8399018B2 (en) * | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
US8496957B2 (en) * | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
JP5421366B2 (en) * | 2008-07-21 | 2014-02-19 | オトノミ―,インク. | Controlled release otic structure modulating and innate immune system modulating compounds and methods for treatment of otic disorders |
US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
US8784870B2 (en) * | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
AU2009307825A1 (en) | 2008-10-22 | 2010-04-29 | Rick FRIEDMAN | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
KR20100079830A (en) * | 2008-12-31 | 2010-07-08 | 삼성정밀화학 주식회사 | Method for preparing toner having narrow particle size distribution |
US20180009767A9 (en) | 2009-03-19 | 2018-01-11 | The Johns Hopkins University | Psma targeted fluorescent agents for image guided surgery |
EP3964498A1 (en) | 2009-03-19 | 2022-03-09 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
US8273725B2 (en) | 2009-09-10 | 2012-09-25 | Genzyme Corporation | Stable hyaluronan/steroid formulation |
WO2011135585A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Aqueous pharmaceutical solution of ciclesonide |
WO2012150131A1 (en) | 2011-05-03 | 2012-11-08 | Chiesi Farmaceutici S.P.A. | Improved suspension formulation of a corticosteroid for administration by inhalation |
MX362187B (en) * | 2013-03-15 | 2019-01-08 | Oakwood Laboratories | Sustained release microspheres and method of producing the same. |
AU2014311358A1 (en) | 2013-08-27 | 2016-04-07 | Otonomy, Inc. | Treatment of pediatric otic disorders |
NO3193835T3 (en) * | 2014-09-15 | 2018-08-04 | ||
US11040004B2 (en) | 2016-09-16 | 2021-06-22 | Otonomy, Inc. | Otic gel formulations for treating otitis externa |
WO2018232280A1 (en) | 2017-06-15 | 2018-12-20 | The Johns Hopkins University | Psma targeted fluorescent agents for image guided surgery |
AU2018318123A1 (en) | 2017-08-15 | 2020-03-19 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
CN107510687B (en) * | 2017-08-18 | 2020-07-03 | 南京海纳医药科技股份有限公司 | Inhalation suspension containing formoterol and budesonide for atomization and preparation method thereof |
CN108175763B (en) * | 2017-12-19 | 2020-09-11 | 亿腾医药(苏州)有限公司 | Budesonide sterile raw material and preparation method of suspension for inhalation thereof |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3337400A (en) * | 1965-10-08 | 1967-08-22 | Joel P Smith | Aqueous post-surgical injection by infiltration with a local anesthetic, a substantially water-insoluble, local anti-inflammatory gluco corticoid, and an antibiotic |
US3692430A (en) * | 1971-06-18 | 1972-09-19 | John W Timmons | Liquid pumping system |
US3992534A (en) * | 1972-05-19 | 1976-11-16 | Ab Bofors | Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods |
US4263253A (en) * | 1978-08-25 | 1981-04-21 | Bayer Aktiengesellschaft | Process for rendering solids sterile |
US5049389A (en) * | 1988-12-14 | 1991-09-17 | Liposome Technology, Inc. | Novel liposome composition for the treatment of interstitial lung diseases |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US5407926A (en) * | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5556964A (en) * | 1989-10-02 | 1996-09-17 | Aktiebolaget Astra | Process for the manufacture of budesonide |
US5637620A (en) * | 1993-08-27 | 1997-06-10 | Astra Aktiebolag | Micro formoterol particles |
US5700794A (en) * | 1994-10-13 | 1997-12-23 | Alcon Laboratories Inc. | Treatment of ocular hypotony |
US5792758A (en) * | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
US5858998A (en) * | 1997-09-26 | 1999-01-12 | Dr. Falk Pharma Gmbh | Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases |
US6066292A (en) * | 1997-12-19 | 2000-05-23 | Bayer Corporation | Sterilization process for pharmaceutical suspensions |
US6153607A (en) * | 1995-12-04 | 2000-11-28 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover) |
US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US6291445B1 (en) * | 1996-12-05 | 2001-09-18 | Astra Aktiebolag | Low dose budesonide formulations and uses thereof |
US6468958B2 (en) * | 1995-03-15 | 2002-10-22 | Ciba Specialty Chemicals Corporation | Biphenyl-substituted triazines |
US6863865B2 (en) * | 2000-11-24 | 2005-03-08 | Breath Limited | Sterilization of pharmaceuticals |
US20050089476A1 (en) * | 2003-10-22 | 2005-04-28 | MONTERESEARCH S.r.I. | Process for the preparation of pharmaceutical suspensions for inhalation |
US20050201888A1 (en) * | 2004-03-12 | 2005-09-15 | Cipla Limited | Sterilization process |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US396430A (en) * | 1889-01-22 | Helm reichel | ||
US3962430A (en) * | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
PT69652A (en) | 1979-05-22 | 1979-06-01 | Quatrum Empresa Nacional De Qu | PROCESS FOR THE STERILIZATION OF NON-STABLE PRODUCTS AT HIGH TEMPERATURES NAMELY STEROID IN POWDER FORM CONTAINED IN A CLOSED PACKAGING |
JPS5732212A (en) | 1980-08-07 | 1982-02-20 | Mitsui Toatsu Chem Inc | Sterilizing method of acetylsalicylate salt |
JPH0660106B2 (en) | 1985-11-14 | 1994-08-10 | 徳男 斎藤 | Manufacturing method of sterile pills mainly composed of crude drugs |
US5380645A (en) * | 1989-03-16 | 1995-01-10 | The Johns Hopkins University | Generalized method for assessment of colorectal carcinoma |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
PL164294B1 (en) | 1990-12-20 | 1994-07-29 | Inst Farmaceutyczny | Method of obtaining a diasteroisomer (22r) of budezonide |
US5491062A (en) * | 1993-11-23 | 1996-02-13 | Stratagene | Polynucleotide amplification mycoplasma assay, primers, and kits therefore |
US5843644A (en) * | 1994-03-01 | 1998-12-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe |
GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
US5580728A (en) * | 1994-06-17 | 1996-12-03 | Perlin; Mark W. | Method and system for genotyping |
WO1996009410A1 (en) * | 1994-09-23 | 1996-03-28 | Finkelstein Sydney D | Topographic genotyping |
JPH10506406A (en) | 1994-09-29 | 1998-06-23 | アンダリス、リミテッド | Spray-dried fine particles as therapeutic vehicles |
SE9501384D0 (en) * | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
AU6290396A (en) * | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal mast cell stabilizers and topical nasal steroids |
JPH0930988A (en) * | 1995-07-21 | 1997-02-04 | Sumitomo Osaka Cement Co Ltd | Sustained release porous ceramic molding for medicine and its production |
WO1999018971A1 (en) | 1997-10-09 | 1999-04-22 | Schering Corporation | Mometasone furoate suspensions for nebulization |
SE9704186D0 (en) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
EP1476201B1 (en) | 2002-02-19 | 2008-12-24 | Resolution Chemicals Limited | Solvent-based sterilisation of steroids |
ITMI20022674A1 (en) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | PROCEDURE FOR THE PREPARATION OF STERILE FORMULATIONS BASED ON MICRONIZED CRYSTALLINE PHARMACEUTICAL ACTIVE SUBSTANCES TO BE ADMINISTERED AS WATER SUSPENSION BY INHALATION. |
-
1997
- 1997-11-14 SE SE9704186A patent/SE9704186D0/en unknown
-
1998
- 1998-11-02 TW TW087118179A patent/TWI242436B/en not_active IP Right Cessation
- 1998-11-09 ZA ZA9810217A patent/ZA9810217B/en unknown
- 1998-11-10 MY MYPI98005104A patent/MY118856A/en unknown
- 1998-11-11 AT AT98956058T patent/ATE259642T1/en active
- 1998-11-11 CN CNB988131099A patent/CN1173702C/en not_active Expired - Lifetime
- 1998-11-11 WO PCT/SE1998/002039 patent/WO1999025359A1/en active IP Right Grant
- 1998-11-11 ES ES98956058T patent/ES2214749T3/en not_active Expired - Lifetime
- 1998-11-11 DK DK98956058T patent/DK1032396T3/en active
- 1998-11-11 AU AU12666/99A patent/AU744992B2/en not_active Expired
- 1998-11-11 PT PT98956058T patent/PT1032396E/en unknown
- 1998-11-11 JP JP2000520792A patent/JP4598268B2/en not_active Expired - Lifetime
- 1998-11-11 NZ NZ504273A patent/NZ504273A/en not_active IP Right Cessation
- 1998-11-11 DE DE1998621796 patent/DE69821796T2/en not_active Expired - Lifetime
- 1998-11-11 BR BR9814118-0A patent/BR9814118A/en not_active Application Discontinuation
- 1998-11-11 US US09/230,781 patent/US6392036B1/en not_active Expired - Lifetime
- 1998-11-11 IL IL13608698A patent/IL136086A/en not_active IP Right Cessation
- 1998-11-11 CA CA002310222A patent/CA2310222C/en not_active Expired - Lifetime
- 1998-11-11 KR KR1020007005212A patent/KR100571075B1/en not_active IP Right Cessation
- 1998-11-11 EP EP98956058A patent/EP1032396B1/en not_active Expired - Lifetime
- 1998-11-13 AR ARP980105761A patent/AR013765A1/en active IP Right Grant
-
1999
- 1999-01-05 SA SA99190966A patent/SA99190966B1/en unknown
-
2000
- 2000-05-12 NO NO20002470A patent/NO327391B1/en not_active IP Right Cessation
-
2001
- 2001-03-02 HK HK01101540A patent/HK1030549A1/en not_active IP Right Cessation
- 2001-11-27 US US09/993,669 patent/US7524834B2/en not_active Expired - Fee Related
-
2007
- 2007-03-23 US US11/690,537 patent/US20070197489A1/en not_active Abandoned
-
2009
- 2009-12-25 JP JP2009293641A patent/JP2010070567A/en active Pending
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3337400A (en) * | 1965-10-08 | 1967-08-22 | Joel P Smith | Aqueous post-surgical injection by infiltration with a local anesthetic, a substantially water-insoluble, local anti-inflammatory gluco corticoid, and an antibiotic |
US3692430A (en) * | 1971-06-18 | 1972-09-19 | John W Timmons | Liquid pumping system |
US3992534A (en) * | 1972-05-19 | 1976-11-16 | Ab Bofors | Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods |
US4263253A (en) * | 1978-08-25 | 1981-04-21 | Bayer Aktiengesellschaft | Process for rendering solids sterile |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US5407926A (en) * | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
US5049389A (en) * | 1988-12-14 | 1991-09-17 | Liposome Technology, Inc. | Novel liposome composition for the treatment of interstitial lung diseases |
US5556964A (en) * | 1989-10-02 | 1996-09-17 | Aktiebolaget Astra | Process for the manufacture of budesonide |
US5637620A (en) * | 1993-08-27 | 1997-06-10 | Astra Aktiebolag | Micro formoterol particles |
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5700794A (en) * | 1994-10-13 | 1997-12-23 | Alcon Laboratories Inc. | Treatment of ocular hypotony |
US6468958B2 (en) * | 1995-03-15 | 2002-10-22 | Ciba Specialty Chemicals Corporation | Biphenyl-substituted triazines |
US6153607A (en) * | 1995-12-04 | 2000-11-28 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover) |
US5792758A (en) * | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
US6291445B1 (en) * | 1996-12-05 | 2001-09-18 | Astra Aktiebolag | Low dose budesonide formulations and uses thereof |
US5858998A (en) * | 1997-09-26 | 1999-01-12 | Dr. Falk Pharma Gmbh | Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases |
US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
US6066292A (en) * | 1997-12-19 | 2000-05-23 | Bayer Corporation | Sterilization process for pharmaceutical suspensions |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US6863865B2 (en) * | 2000-11-24 | 2005-03-08 | Breath Limited | Sterilization of pharmaceuticals |
US20050089476A1 (en) * | 2003-10-22 | 2005-04-28 | MONTERESEARCH S.r.I. | Process for the preparation of pharmaceutical suspensions for inhalation |
US20050201888A1 (en) * | 2004-03-12 | 2005-09-15 | Cipla Limited | Sterilization process |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6392036B1 (en) | Dry heat sterilization of a glucocorticosteroid | |
EP1126823B1 (en) | A process for the preparation of sterile therapeutically acceptable beclomethasone dipropionate | |
US7892483B2 (en) | Sterilization process | |
EP2805712B1 (en) | Heat sterilization of glucocorticoidsteriods | |
JP5001657B2 (en) | Aqueous suspension of ciclesonide for nebulization | |
JP4712689B2 (en) | Sterilization of beclomethasone drug particles for pulmonary delivery | |
MXPA00004648A (en) | New composition of matter | |
WO2022231531A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
US20150290220A1 (en) | Pharmaceutical formualtions comprising a Gluococorticosteroid | |
MXPA06006537A (en) | Aqueous suspensions of ciclesonide for nebulisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTRA AKTIEBOLAG, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KARLSSON, ANN-KRISTIN;LARRIVEE-ELKINS, CHERYL;MOLIN, OVE;REEL/FRAME:019110/0865;SIGNING DATES FROM 19981214 TO 19990120 |
|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: CERTIFICATE OF REGISTRATION;ASSIGNOR:AKTIEBOLAG, ASTRA;REEL/FRAME:019175/0721 Effective date: 20000215 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |